- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07717970
Metabolomics-Driven Insights Into Ultra-Processed Foods
Metabolomics-Driven Insights Into Ultra-Processed Foods: Identifying High-Risk UPF Subtypes for T2D Prevention
The goal of this dietary intervention study in generally healthy adults is to develop new ways to use blood samples to measure the common types of highly processed foods and beverages that people eat on a regular basis. The main aims to answer are:
What small molecules are elevated in blood after eating different types of highly processed foods and beverages consistently for 1 week?
Researchers will compare 3 different test diets with 1 control diet that does not have any highly processed foods in the same individuals to see which circulating blood markers change.
Participants will:
- Complete 3 diet phases, each 2 weeks long
- Receive a meal plan and study foods and beverages to follow for each 2-week phase
- Come to the clinic every week for blood draws, urine samples, and stool collection kits
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Deirdre K Tobias, ScD
- Numero di telefono: 617-278-0844
- Email: dtobias@bwh.harvard.edu
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Brigham and Women's Hopital Center for Clinical Investigation
-
Contatto:
- Yemi Talabi-Oates, MBA
- Numero di telefono: 617-732-8750
- Email: cci@bwh.harvard.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adults, ages 20 to 65 years.
- BMI 18.5 to 39.9 kg/m2.
- No known food allergies, intolerances, or sensitivities (e.g., gluten, dairy, monosodium-glutamate).
- Not following a restrictive diet for health, religious, or other reasons (e.g., vegetarian, vegan).
- Willingness to participate and give informed consent.
- Willingness to consume dietary intervention foods and beverages.
Exclusion Criteria:
- BMI <18.5 or >39.9 kg/m2.
- Pregnant, lactating, or planning on becoming pregnant in the next 6 months.
- History of bariatric surgery.
- Currently taking medications impacting appetite or body weight.
- History of major chronic diseases, including cardiovascular disease, type 1 or 2 diabetes, major gastrointestinal conditions, uncontrolled hypertension (seated blood pressure systolic >140 mmHg or diastolic >90 mmHg), history of invasive cancer, current use of immunosuppressants, and other major chronic diseases and conditions affecting participation, adherence, or study endpoints.
- Unwilling or unable to comply with all in person scheduled visits, dietary protocols, study protocol, and other study procedures.
- Food allergies or aversions to the foods provided in the dietary interventions.
- Non-English speaking.
- Other members of the same household are already participating in the research study.
- Planning on moving out of the Boston area in the next 6 months.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Sequence 1
Participants receive Diet A, followed by Diet B, followed by Diet C.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Sperimentale: Sequence 2
Participants receive Diet A, followed by Diet C, followed by Diet B.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Sperimentale: Sequence 3
Participants receive Diet B, followed by Diet A, followed by Diet C.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Sperimentale: Sequence 4
Participants receive Diet B, followed by Diet C, followed by Diet A.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Sperimentale: Sequence 5
Participants receive Diet C, followed by Diet A, followed by Diet B.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
|
Sperimentale: Sequence 6
Participants receive Diet C, followed by Diet B, followed by Diet A.
|
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consistently of starchy foods and refined grain products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of meat, fish, and bread products.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
The 2-week diet phase includes a standardized control run-in diet with non-UPFs only for 7 days, immediately followed by a 7-day UPF test diet with ~60% of calories from UPFs consisting of dairy products, including cheese and cream.
Participants receive all study-provided meals and snacks.
The diets are standardized and consumed during the assigned intervention period as part of the randomized crossover feeding trial.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Within-person metabolomic response during each UPF test diet, compared to the paired non-UPF control diet.
Lasso di tempo: Day 0, Day 7, and Day 14 of each dietary intervention period
|
The primary outcome for this study is within-person metabolomic response during each UPF test diet, compared to the paired non-UPF control diet.
Metabolomic responses will be quantified from metabolite concentrations (e.g., relative abundance) measured in fasting plasma samples collected at day 0, day 7, and day 14 in each diet phase.
|
Day 0, Day 7, and Day 14 of each dietary intervention period
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Deirdre K Tobias, ScD, Brigham and Women's Hospital
- Investigatore principale: Shilpa Bhupathiraju, PhD, Brigham and Women's Hospital
- Investigatore principale: Frank B Hu, MD PhD, Harvard School of Public Health (HSPH)
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Tecniche investigative
- Tecniche di laboratorio clinico
- Tecniche e procedure diagnostiche
- Diagnosi
- Tecniche citologiche
- Tecniche istologiche
- Tecniche genetiche
- Tecniche di preparazione istocitologica
- Ibridazione in situ
- Colorazione ed etichettatura
- Analisi citogenetica
- Ibridazione degli acidi nucleici
- Ibridazione in situ, fluorescenza
Altri numeri di identificazione dello studio
- 2026P001870
- 1R01DK145733-01A1 (Altro numero di sovvenzione/finanziamento: NIH (Pending))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .